According to a bulk of previous studies, the human's immune system reaches its peak state around the age of 30 and gradually declines with age. The decline in immunity also means that the ability of immune cells to combat foreign pathogens also decreases, resulting in the development of infectious diseases or the increasing risk of cancers.

In the United States, Japan and other advanced medical countries see immune cell therapy as a routine medical treatment, immune cell therapy is a new trend of modern cancer treatment. As well as that, the key point of immune cell therapy is the good quality of immune cells. Therefore, storing healthy and high quality immune cells is a guarantee and hope in the future as well.

FHB immune cell bank is satisfied the regulation of GTP. The quality control of immune cell bank is satisfied TAF ISO/ IEC 17025; moreover, the GMP-grade reagents are used to cell preservation. The quality of immune cell bank achieves medical grade for clinical use. FHB has completed the phase 1 trial of immune cell therapy by the cooperation with medical centers. Based on these experience, FHB is able to provide a high quality of customized immune cell therapy in the future.